Key Takeaways:

• Amorepacific has made a strategic investment in Junevity through its corporate venture arm. 
• The partnership builds on Dr. Janine Sengstack’s research at the University of California San Francisco.
• RESET uses human disease omics, genetic linkages, and ML/AI to identify novel transcription factor targets.

Amorepacific and Junevity have partnered to develop next-generation skin rejuvenation products.

WHO: Junevity is a biotechnology company developing siRNA therapeutics to reset global gene networks for longevity. The Junevity RESET Platform is the first to use human disease omics, human genetic linkages, and ML/AI to identify novel transcription factor targets and repress them with siRNA therapeutics. Initial programs are in siRNA for obesity, with collaborations in aesthetics and neurodegeneration. Based in San Francisco and founded out of University of California San Francisco in 2023, Junevity’s mission is to increase lifespan and healthspan.

Founded in 1945, Amorepacific is Korea’s leading global beauty company, with a portfolio spanning skincare, makeup, haircare, inner beauty, and beauty technology. With more than 70 years of authentic, research-driven innovation dating back to the establishment of Korea’s first cosmetics laboratory in 1954, Amorepacific has built deep expertise in skin biology, beauty science, and product development. The company continues to explore new frontiers in beauty through research-driven innovation, including a growing focus on skin longevity, advanced biotechnology, and collaboration across disciplines.

WHY: Junevity will apply its RESET Platform to discover novel skin-aging pathways for cosmetics, pairing its...